OXi-4503 tetrasodium is primarily used in research and clinical settings as a vascular disrupting agent (VDA). It targets and damages the blood vessels that supply tumors, leading to tumor necrosis and inhibition of cancer cell growth. This compound is particularly valuable in oncology for its ability to selectively disrupt tumor vasculature while minimizing effects on healthy tissues. It is often studied in combination with other anticancer therapies, such as chemotherapy or immunotherapy, to enhance treatment efficacy. OXi-4503 tetrasodium is also explored for its potential in treating solid tumors, including those resistant to conventional therapies. Its application is a promising area of investigation in developing more effective cancer treatments.